For more than a decade, the Alliance for Aging Research has produced Taking a Closer Look at AMD, a brochure that shares the basics of age-related macular degeneration (“AMD”) and that has been used by ophthalmologists and eye care professionals across the country as a resource for their patients. When first published, in addition to sharing the basics of the disease, the brochure shared resources and tips on living with low vision. After many reprints to meet demand, the brochure now also focuses on the exciting treatments and research field of AMD.

Building off this highly successful campaign, the Alliance produced a short, animated film that focuses on prevention, risk factors, symptoms, and treatment of AMD.

In partnership with the Clive Hamilton Sell, M.D. Vision Foundation, and with support from the Sell Foundation and Genentech, the Alliance for Aging Research (Alliance) released a Spanish version of the original pocket film, “Taking a Closer Look at Age-Related Macular Degeneration” titled, “La Degeneración Macular Asociada con la Edad (DMAE).”  In addition, two 30- and 60-second public service announcements were released in English that provided a brief overview of Age-Related Macular Degeneration and directed viewers to more information on-line.

Age-related macular degeneration (AMD) is a leading cause of vision loss in the United States, affecting as many as 11 million Americans. Without proper treatment, AMD can lead to loss of sharp, central vision and cause legal blindness.

The Alliance’s original pocket film gives an overview of the disease—including risk factors, symptoms, diagnosis, treatment options, and the role nutrition and lifestyle play in protecting eyesight. It also addresses some of the challenges of living with AMD, and encourages those diagnosed with the disease to take control of their sight. The film provides a link to www.agingresearch.org/AMD for viewers to visit to learn more about the condition.

The newly released “La Degeneración Macular Asociada con la Edad (DMAE),” along with the 30- and 60-second English videos, were made available to view on YouTube. The 30-, 60-second, and Spanish Versions (along with a version with closed captioning) were also made available for direct download on Vimeo.

The full-length Spanish video was viewed more than 17,000 times on YouTube.

 

View the Entire REPORT: 2018 Taking a Closer Look at AMD_Final Report

CONCLUSION

We thank the Clive Hamilton Sell, M.D. Vision Foundation and Genentech for their generous support of these efforts. The impact results of this campaign were higher than expected, which tells us that television and print PSA placement are natural next steps. We look forward to continuing to raise awareness of Age-Related Macular Degeneration through the Taking a Closer Look at AMD campaign and expanding the reach of this important vision issue even further to improve the health and well-being of older adults.

About Microperimeter

Associated Retina Consultants (ARC) will conduct two new clinical trials for the treatment of Stargardt disease and age-related macular degeneration. Stargardt disease is the most common childhood onset of macular dystrophy with central vision loss and age-related macular degeneration is the leading cause of vision loss among people age 50 or older.

The goal with the new treatment is to prevent progression of these retinal diseases.  Using a technology called microperimetry, the physicians at ARC are able to evaluate small changes in the vision and are capable of assessing the patient’s needs and providing the highest level of care.  The microperimetry measurements will enable ARC to implement clinical trials for the treatment of Stargardt disease and age-related macular degeneration.

“The generous donation of a microperimeter by the Sell foundation will allow us to offer the first clinical trial in Arizona for an inherited eye disease.” said Benjamin Bakall, MD, PhD, the director for the Inherited Retinal Dystrophy and Visual Function clinic at ARC.  “We know that in Stargardt disease there is accumulation of toxic compounds that cause the degeneration of the retina and the treatment in this clinical trial is engineered to prevent the formation of these compounds.  The same treatment will be used for age-related macular degeneration, which has a similar disease process. The microperimeter will enable us to evaluate and treat patients more effectively and will advance the treatment of Stargardt disease and dry age-related macular degeneration, for where there currently is no cure”.

Intravitreal Methotrexate for Mantle Cell Lymphoma Infiltration of the Optic Nerves: A Case Report

Authors:  James R. Singer, DO,*  Archana K. Nigalye, MBBS, DNB,* Mary T. Champion, MD,* Matthew J. Welch, MD*†

PURPOSE: To report the successful treatment of a 78-year-old woman with bilateral mantle cell lymphoma involving the optic nerves. Chemotherapy initially was administered in the form of intravitreal methotrexate (MTX) monotherapy and was subsequently combined with systemic ibrutinib.

METHODS: Retrospective case report.  The diagnosis of CD5-negative mantle cell lymphoma was confirmed via immunohistopathological analysis of an axillary lymph node.  Serial ophthalmologic examinations in conjunction with fluorescein angiography, fundus photography, and spectral domain optical coherence tomography were used to assess the treatment response.

RESULTS: Prompt improvement in optic nerve infiltration, no significant side effects, and excellent tolerability were noted after two weekly injections of unilateral intravitreal MTX monotherapy.  Combined systemic treatment with ibrutinib and bilateral weekly MTX intravitreal injections then resulted in continued regression of optic nerve infiltration bilaterally as confirmed by serial fundus photography and optical coherence tomography.  After eight additional bilateral weekly injections, a mild MTX-associated keratopathy developed, which resolved promptly with cessation, but with continued ibrutinib treatment, the optic nerves revealed near-complete resolution of the lymphomatous infiltration and the visual acuity improved.

CONCLUSION: Intravitreal MTX injections and systemic ibrutinib may represent effective treatment options for patients diagnosed with intraocular mantle cell lymphoma.

RETINAL CASES & BRIEF REPORTS 0:1—5, 2016

From the *Associated Retina Consultants, Phoenix, Arizona; and †The University of Arizona College of Medicine-Phoenix, Phoenix, Arizona.

Click here to download the full article.

The Clive Hamilton Sell, M.D. Vision Foundation

The retina specialists at Associated Retina Consultants (ARC) recently held their annual retina symposium, a continuing medical education (CME) event, for ophthalmologists across the state of Arizona. Physicians received new information and updates regarding retinal conditions, treatment methods and recent research and progress made to advance the retina vitreous field.

“This is one of the largest gatherings of ophthalmologists and retina specialists across Arizona, and our team is pleased to have the opportunity to collaborate and share our ongoing research, findings and cutting-edge treatments with our trusted colleagues,” said Dr. Alan J. Gordon, President of ARC. “Thank you to all of ARC’s referring practice physicians for your attendance and continued support of our retina practice. We appreciate the trust you place in our team to provide the best possible care for your patients that are suffering from retinal disease.”

The bittersweet highlight of the retina symposium was the introduction of The Clive Hamilton Sell M.D. Vision Foundation. Many physicians at the symposium were not only colleagues of Dr. Sell, but they also regarded Dr. Sell as a beloved friend. Associated Retina Consultants was proud to announce the foundation and to present the new, inspiring video of Dr. Sell’s life and the legacy of his work in the retinal field.

The Sell Foundation is a non-profit organization committed to education, training, research and public awareness of programs related to diseases of the retina. This foundation is named after Associated Retina Consultants’ late partner, friend and visionary retinal surgeon — Dr. Clive Hamilton Sell.

The Associated Retina Consultants retina symposium was held on Saturday, April 23, from 7:30 a.m. to 1:30 p.m. at the Talking Stick Resort in Scottsdale, Arizona. Ophthalmologists were invited from practices across Arizona to attend and earn continuing medical education credits (CME).

To learn more about Dr. Sell and The Clive Hamilton Sell M.D. Vision Foundation, visit sellfoundation.org.  

Watch The Sell Foundation video: https://youtu.be/KKqff0J8_jA